Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.

Ciara Louise Freeman Reginald Atkins Indumathy Varadarajan Meghan Menges Jeffrey Edelman Rachid C Baz Jason Brayer Omar Castaneda Puglianini Jose Leonel Ochoa-Bayona Taiga Nishihori Kenneth H Shain Bijal D Shah Dung Tsa Chen Linda Kelley Domenico Coppola Melissa Alsina Scott J Antonia Claudio Anasetti Frederick L Locke

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Two doses of DC:Ad-S, one given immediately before and another after ASCT, were feasible and safe. A high frequency of vaccine-specific immune responses was seen in combination with durable clinical outcomes, supporting ongoing investigation into the potential of this approach.

Keyphrases

dendritic cells
high frequency
immune response
transcranial magnetic stimulation
regulatory t cells
toll like receptor
multiple myeloma
bone marrow
cell therapy
platelet rich plasma
mesenchymal stem cells
risk assessment
climate change